Clinical Trial Update: Nivolumab Plus Standard Dose Bevacizumab Versus Nivolumab Plus Low Dose Bevacizumab in GBM [Phase 2]

View source ↗

Summary

Phase 2 study in glioblastoma comparing nivolumab plus standard-dose bevacizumab versus nivolumab plus low-dose bevacizumab; results were posted in January 2025…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• nivolumab (nivolumab)

Snippet

Sponsor: David Peereboom | Conditions: Glioblastoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2025-01-13